nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrimeprazine—CYP1A2—Anagrelide—hematologic cancer	0.061	0.105	CbGbCtD
Methotrimeprazine—CYP2E1—Thalidomide—hematologic cancer	0.039	0.0672	CbGbCtD
Methotrimeprazine—CYP2E1—Dacarbazine—hematologic cancer	0.0336	0.0578	CbGbCtD
Methotrimeprazine—CYP2D6—Lomustine—hematologic cancer	0.0324	0.0557	CbGbCtD
Methotrimeprazine—CYP1A2—Carmustine—hematologic cancer	0.0321	0.0551	CbGbCtD
Methotrimeprazine—CYP2D6—Idarubicin—hematologic cancer	0.0289	0.0497	CbGbCtD
Methotrimeprazine—CYP1A2—Methoxsalen—hematologic cancer	0.0273	0.0469	CbGbCtD
Methotrimeprazine—CYP2E1—Mitoxantrone—hematologic cancer	0.0261	0.0448	CbGbCtD
Methotrimeprazine—CYP1A2—Bortezomib—hematologic cancer	0.0259	0.0446	CbGbCtD
Methotrimeprazine—CYP1A2—Daunorubicin—hematologic cancer	0.0248	0.0427	CbGbCtD
Methotrimeprazine—CYP2D6—Hydroxyurea—hematologic cancer	0.0246	0.0422	CbGbCtD
Methotrimeprazine—CYP1A2—Alitretinoin—hematologic cancer	0.0243	0.0418	CbGbCtD
Methotrimeprazine—CYP1A2—Thalidomide—hematologic cancer	0.0226	0.0388	CbGbCtD
Methotrimeprazine—CYP2D6—Bortezomib—hematologic cancer	0.0214	0.0367	CbGbCtD
Methotrimeprazine—CYP1A2—Dacarbazine—hematologic cancer	0.0194	0.0334	CbGbCtD
Methotrimeprazine—CYP1A2—Imatinib—hematologic cancer	0.019	0.0327	CbGbCtD
Methotrimeprazine—CYP2E1—Etoposide—hematologic cancer	0.0164	0.0283	CbGbCtD
Methotrimeprazine—CYP2D6—Imatinib—hematologic cancer	0.0156	0.0269	CbGbCtD
Methotrimeprazine—CYP1A2—Dasatinib—hematologic cancer	0.0153	0.0262	CbGbCtD
Methotrimeprazine—CYP2D6—Nilotinib—hematologic cancer	0.0142	0.0245	CbGbCtD
Methotrimeprazine—CYP2D6—Vinorelbine—hematologic cancer	0.0141	0.0243	CbGbCtD
Methotrimeprazine—CYP2E1—Dexamethasone—hematologic cancer	0.0135	0.0232	CbGbCtD
Methotrimeprazine—CYP1A2—Etoposide—hematologic cancer	0.0095	0.0163	CbGbCtD
Methotrimeprazine—CYP2D6—Vinblastine—hematologic cancer	0.00869	0.0149	CbGbCtD
Methotrimeprazine—CYP2D6—Dexamethasone—hematologic cancer	0.00644	0.0111	CbGbCtD
Methotrimeprazine—CYP2D6—Doxorubicin—hematologic cancer	0.00534	0.00918	CbGbCtD
Methotrimeprazine—Weight increased—Ruxolitinib—hematologic cancer	0.00219	0.011	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Pentostatin—hematologic cancer	0.00219	0.011	CcSEcCtD
Methotrimeprazine—Liver injury—Bexarotene—hematologic cancer	0.00215	0.0108	CcSEcCtD
Methotrimeprazine—Sudden death—Mitoxantrone—hematologic cancer	0.0021	0.0105	CcSEcCtD
Methotrimeprazine—Sudden death—Irinotecan—hematologic cancer	0.0021	0.0105	CcSEcCtD
Methotrimeprazine—Drug interaction—Busulfan—hematologic cancer	0.00205	0.0103	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Bexarotene—hematologic cancer	0.00181	0.00909	CcSEcCtD
Methotrimeprazine—Photosensitivity—Anagrelide—hematologic cancer	0.00181	0.00909	CcSEcCtD
Methotrimeprazine—Drug interaction—Imatinib—hematologic cancer	0.00179	0.009	CcSEcCtD
Methotrimeprazine—Photosensitivity—Procarbazine—hematologic cancer	0.00153	0.00767	CcSEcCtD
Methotrimeprazine—Jaundice—Mechlorethamine—hematologic cancer	0.00152	0.00763	CcSEcCtD
Methotrimeprazine—Photosensitivity—Dasatinib—hematologic cancer	0.0015	0.00752	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Melphalan—hematologic cancer	0.00149	0.00749	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Mechlorethamine—hematologic cancer	0.00145	0.00731	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Anagrelide—hematologic cancer	0.00145	0.00729	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Lenalidomide—hematologic cancer	0.00145	0.00728	CcSEcCtD
Methotrimeprazine—Photosensitivity—Nilotinib—hematologic cancer	0.00138	0.00694	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Bortezomib—hematologic cancer	0.00133	0.0067	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Methoxsalen—hematologic cancer	0.00131	0.0066	CcSEcCtD
Methotrimeprazine—Drug interaction—Thalidomide—hematologic cancer	0.0013	0.00651	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Anagrelide—hematologic cancer	0.00125	0.0063	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Pentostatin—hematologic cancer	0.00125	0.0063	CcSEcCtD
Methotrimeprazine—Weight increased—Anagrelide—hematologic cancer	0.00125	0.00628	CcSEcCtD
Methotrimeprazine—Urinary retention—Bexarotene—hematologic cancer	0.00125	0.00628	CcSEcCtD
Methotrimeprazine—Drug interaction—Carmustine—hematologic cancer	0.00125	0.00626	CcSEcCtD
Methotrimeprazine—Drug interaction—Alitretinoin—hematologic cancer	0.00123	0.0062	CcSEcCtD
Methotrimeprazine—Drug interaction—Ifosfamide—hematologic cancer	0.00122	0.00612	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Thalidomide—hematologic cancer	0.0012	0.00604	CcSEcCtD
Methotrimeprazine—Jaundice—Clofarabine—hematologic cancer	0.0012	0.00602	CcSEcCtD
Methotrimeprazine—Drug interaction—Vincristine—hematologic cancer	0.00119	0.00597	CcSEcCtD
Methotrimeprazine—Liver injury—Cisplatin—hematologic cancer	0.00116	0.00582	CcSEcCtD
Methotrimeprazine—DRD5—hematopoietic system—hematologic cancer	0.00115	0.0905	CbGeAlD
Methotrimeprazine—Hepatocellular injury—Alitretinoin—hematologic cancer	0.00114	0.00575	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Pentostatin—hematologic cancer	0.00114	0.00574	CcSEcCtD
Methotrimeprazine—Drug interaction—Gemcitabine—hematologic cancer	0.00113	0.00567	CcSEcCtD
Methotrimeprazine—Weight increased—Busulfan—hematologic cancer	0.00109	0.00546	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Procarbazine—hematologic cancer	0.00106	0.00531	CcSEcCtD
Methotrimeprazine—Sudden death—Methotrexate—hematologic cancer	0.00105	0.00525	CcSEcCtD
Methotrimeprazine—Jaundice—Busulfan—hematologic cancer	0.00104	0.00521	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Dasatinib—hematologic cancer	0.00104	0.00521	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Bexarotene—hematologic cancer	0.00104	0.00521	CcSEcCtD
Methotrimeprazine—Weight increased—Dasatinib—hematologic cancer	0.00103	0.00519	CcSEcCtD
Methotrimeprazine—Weight increased—Bexarotene—hematologic cancer	0.00103	0.00519	CcSEcCtD
Methotrimeprazine—Drowsiness—Procarbazine—hematologic cancer	0.00103	0.00519	CcSEcCtD
Methotrimeprazine—Jaundice—Procarbazine—hematologic cancer	0.00101	0.00506	CcSEcCtD
Methotrimeprazine—Urinary retention—Lenalidomide—hematologic cancer	0.001	0.00503	CcSEcCtD
Methotrimeprazine—Photosensitivity—Thalidomide—hematologic cancer	0.000994	0.005	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Busulfan—hematologic cancer	0.000994	0.00499	CcSEcCtD
Methotrimeprazine—Constipation—Vorinostat—hematologic cancer	0.00099	0.00497	CcSEcCtD
Methotrimeprazine—Jaundice—Bexarotene—hematologic cancer	0.000987	0.00496	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Cisplatin—hematologic cancer	0.000975	0.0049	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Nilotinib—hematologic cancer	0.000958	0.00481	CcSEcCtD
Methotrimeprazine—Weight increased—Nilotinib—hematologic cancer	0.000955	0.0048	CcSEcCtD
Methotrimeprazine—DRD4—testis—hematologic cancer	0.000953	0.0753	CbGeAlD
Methotrimeprazine—Photosensitivity reaction—Imatinib—hematologic cancer	0.000952	0.00478	CcSEcCtD
Methotrimeprazine—Weight increased—Imatinib—hematologic cancer	0.000949	0.00477	CcSEcCtD
Methotrimeprazine—Photosensitivity—Alitretinoin—hematologic cancer	0.000946	0.00475	CcSEcCtD
Methotrimeprazine—Jaundice—Chlorambucil—hematologic cancer	0.000932	0.00468	CcSEcCtD
Methotrimeprazine—Urinary retention—Bortezomib—hematologic cancer	0.000921	0.00462	CcSEcCtD
Methotrimeprazine—Jaundice—Nilotinib—hematologic cancer	0.000912	0.00458	CcSEcCtD
Methotrimeprazine—Jaundice—Imatinib—hematologic cancer	0.000907	0.00455	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Bortezomib—hematologic cancer	0.000884	0.00444	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Imatinib—hematologic cancer	0.000868	0.00436	CcSEcCtD
Methotrimeprazine—Urinary retention—Thiotepa—hematologic cancer	0.000858	0.00431	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Lenalidomide—hematologic cancer	0.00083	0.00417	CcSEcCtD
Methotrimeprazine—Weight increased—Lenalidomide—hematologic cancer	0.000828	0.00416	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Vinblastine—hematologic cancer	0.000818	0.00411	CcSEcCtD
Methotrimeprazine—Weight increased—Hydroxyurea—hematologic cancer	0.000816	0.0041	CcSEcCtD
Methotrimeprazine—Jaundice—Melphalan—hematologic cancer	0.000813	0.00408	CcSEcCtD
Methotrimeprazine—Drowsiness—Hydroxyurea—hematologic cancer	0.000799	0.00402	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Thalidomide—hematologic cancer	0.000797	0.00401	CcSEcCtD
Methotrimeprazine—Urinary retention—Ifosfamide—hematologic cancer	0.000781	0.00392	CcSEcCtD
Methotrimeprazine—Tachycardia—Daunorubicin—hematologic cancer	0.000766	0.00385	CcSEcCtD
Methotrimeprazine—Tachycardia—Clofarabine—hematologic cancer	0.000766	0.00385	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Bortezomib—hematologic cancer	0.000764	0.00384	CcSEcCtD
Methotrimeprazine—Tachycardia—Pentostatin—hematologic cancer	0.000762	0.00383	CcSEcCtD
Methotrimeprazine—Tachycardia—Anagrelide—hematologic cancer	0.000762	0.00383	CcSEcCtD
Methotrimeprazine—Weight increased—Bortezomib—hematologic cancer	0.000762	0.00383	CcSEcCtD
Methotrimeprazine—Urinary retention—Vincristine—hematologic cancer	0.000761	0.00382	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Lenalidomide—hematologic cancer	0.000757	0.0038	CcSEcCtD
Methotrimeprazine—Somnolence—Nelarabine—hematologic cancer	0.000745	0.00374	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Mechlorethamine—hematologic cancer	0.000732	0.00368	CcSEcCtD
Methotrimeprazine—CHRM4—testis—hematologic cancer	0.00072	0.0569	CbGeAlD
Methotrimeprazine—Constipation—Nelarabine—hematologic cancer	0.000717	0.0036	CcSEcCtD
Methotrimeprazine—Tachycardia—Teniposide—hematologic cancer	0.000715	0.00359	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Irinotecan—hematologic cancer	0.000712	0.00358	CcSEcCtD
Methotrimeprazine—Weight increased—Thiotepa—hematologic cancer	0.00071	0.00357	CcSEcCtD
Methotrimeprazine—Somnolence—Clofarabine—hematologic cancer	0.000698	0.0035	CcSEcCtD
Methotrimeprazine—Somnolence—Daunorubicin—hematologic cancer	0.000698	0.0035	CcSEcCtD
Methotrimeprazine—Somnolence—Pentostatin—hematologic cancer	0.000694	0.00349	CcSEcCtD
Methotrimeprazine—Somnolence—Anagrelide—hematologic cancer	0.000694	0.00349	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Thalidomide—hematologic cancer	0.000689	0.00346	CcSEcCtD
Methotrimeprazine—Weight increased—Thalidomide—hematologic cancer	0.000687	0.00345	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Vinorelbine—hematologic cancer	0.00068	0.00341	CcSEcCtD
Methotrimeprazine—Jaundice—Thiotepa—hematologic cancer	0.000678	0.00341	CcSEcCtD
Methotrimeprazine—Drowsiness—Thalidomide—hematologic cancer	0.000673	0.00338	CcSEcCtD
Methotrimeprazine—Constipation—Daunorubicin—hematologic cancer	0.000671	0.00337	CcSEcCtD
Methotrimeprazine—Constipation—Pentostatin—hematologic cancer	0.000668	0.00336	CcSEcCtD
Methotrimeprazine—Constipation—Anagrelide—hematologic cancer	0.000668	0.00336	CcSEcCtD
Methotrimeprazine—Tachycardia—Busulfan—hematologic cancer	0.000663	0.00333	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Alitretinoin—hematologic cancer	0.000655	0.00329	CcSEcCtD
Methotrimeprazine—Weight increased—Alitretinoin—hematologic cancer	0.000653	0.00328	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Thiotepa—hematologic cancer	0.000649	0.00326	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Cisplatin—hematologic cancer	0.000647	0.00325	CcSEcCtD
Methotrimeprazine—Tachycardia—Procarbazine—hematologic cancer	0.000643	0.00323	CcSEcCtD
Methotrimeprazine—Drowsiness—Alitretinoin—hematologic cancer	0.00064	0.00322	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Vincristine—hematologic cancer	0.000632	0.00317	CcSEcCtD
Methotrimeprazine—Tachycardia—Dasatinib—hematologic cancer	0.00063	0.00317	CcSEcCtD
Methotrimeprazine—Tachycardia—Bexarotene—hematologic cancer	0.00063	0.00317	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Thalidomide—hematologic cancer	0.000628	0.00315	CcSEcCtD
Methotrimeprazine—Weight increased—Mitoxantrone—hematologic cancer	0.000613	0.00308	CcSEcCtD
Methotrimeprazine—Somnolence—Busulfan—hematologic cancer	0.000604	0.00303	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Methoxsalen—hematologic cancer	0.000603	0.00303	CcSEcCtD
Methotrimeprazine—Drowsiness—Mitoxantrone—hematologic cancer	0.000601	0.00302	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Alitretinoin—hematologic cancer	0.000597	0.003	CcSEcCtD
Methotrimeprazine—Liver injury—Epirubicin—hematologic cancer	0.000595	0.00299	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Ifosfamide—hematologic cancer	0.00059	0.00297	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Mercaptopurine—hematologic cancer	0.000586	0.00294	CcSEcCtD
Methotrimeprazine—Somnolence—Procarbazine—hematologic cancer	0.000586	0.00294	CcSEcCtD
Methotrimeprazine—Jaundice—Irinotecan—hematologic cancer	0.000586	0.00294	CcSEcCtD
Methotrimeprazine—Jaundice—Mitoxantrone—hematologic cancer	0.000586	0.00294	CcSEcCtD
Methotrimeprazine—Tachycardia—Nilotinib—hematologic cancer	0.000582	0.00293	CcSEcCtD
Methotrimeprazine—Constipation—Busulfan—hematologic cancer	0.000581	0.00292	CcSEcCtD
Methotrimeprazine—Tachycardia—Imatinib—hematologic cancer	0.000579	0.00291	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Clofarabine—hematologic cancer	0.000578	0.0029	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Daunorubicin—hematologic cancer	0.000578	0.0029	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Pentostatin—hematologic cancer	0.000575	0.00289	CcSEcCtD
Methotrimeprazine—Somnolence—Bexarotene—hematologic cancer	0.000574	0.00288	CcSEcCtD
Methotrimeprazine—Somnolence—Dasatinib—hematologic cancer	0.000574	0.00288	CcSEcCtD
Methotrimeprazine—Tachycardia—Cladribine—hematologic cancer	0.000569	0.00286	CcSEcCtD
Methotrimeprazine—Constipation—Procarbazine—hematologic cancer	0.000563	0.00283	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Mitoxantrone—hematologic cancer	0.000561	0.00282	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Idarubicin—hematologic cancer	0.000555	0.00279	CcSEcCtD
Methotrimeprazine—Constipation—Bexarotene—hematologic cancer	0.000552	0.00277	CcSEcCtD
Methotrimeprazine—Constipation—Dasatinib—hematologic cancer	0.000552	0.00277	CcSEcCtD
Methotrimeprazine—Constipation—Fludarabine—hematologic cancer	0.000551	0.00277	CcSEcCtD
Methotrimeprazine—Liver injury—Doxorubicin—hematologic cancer	0.000551	0.00277	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Gemcitabine—hematologic cancer	0.000546	0.00274	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Teniposide—hematologic cancer	0.00054	0.00271	CcSEcCtD
Methotrimeprazine—Somnolence—Imatinib—hematologic cancer	0.000527	0.00265	CcSEcCtD
Methotrimeprazine—ADRA1A—hematopoietic system—hematologic cancer	0.000527	0.0417	CbGeAlD
Methotrimeprazine—Tachycardia—Melphalan—hematologic cancer	0.000519	0.00261	CcSEcCtD
Methotrimeprazine—Somnolence—Cladribine—hematologic cancer	0.000518	0.0026	CcSEcCtD
Methotrimeprazine—Constipation—Nilotinib—hematologic cancer	0.00051	0.00256	CcSEcCtD
Methotrimeprazine—Constipation—Imatinib—hematologic cancer	0.000507	0.00255	CcSEcCtD
Methotrimeprazine—Tachycardia—Lenalidomide—hematologic cancer	0.000505	0.00254	CcSEcCtD
Methotrimeprazine—Weight increased—Prednisolone—hematologic cancer	0.000503	0.00253	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Epirubicin—hematologic cancer	0.000501	0.00252	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Busulfan—hematologic cancer	0.0005	0.00251	CcSEcCtD
Methotrimeprazine—Constipation—Cladribine—hematologic cancer	0.000499	0.0025	CcSEcCtD
Methotrimeprazine—Jaundice—Etoposide—hematologic cancer	0.000487	0.00245	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Procarbazine—hematologic cancer	0.000485	0.00244	CcSEcCtD
Methotrimeprazine—Constipation—Vinblastine—hematologic cancer	0.000478	0.0024	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Bexarotene—hematologic cancer	0.000476	0.00239	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Dasatinib—hematologic cancer	0.000476	0.00239	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Fludarabine—hematologic cancer	0.000474	0.00238	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Etoposide—hematologic cancer	0.000466	0.00234	CcSEcCtD
Methotrimeprazine—Tachycardia—Bortezomib—hematologic cancer	0.000464	0.00233	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Doxorubicin—hematologic cancer	0.000463	0.00233	CcSEcCtD
Methotrimeprazine—Weight increased—Triamcinolone—hematologic cancer	0.000463	0.00232	CcSEcCtD
Methotrimeprazine—Somnolence—Lenalidomide—hematologic cancer	0.00046	0.00231	CcSEcCtD
Methotrimeprazine—Tachycardia—Vinorelbine—hematologic cancer	0.000453	0.00228	CcSEcCtD
Methotrimeprazine—Somnolence—Hydroxyurea—hematologic cancer	0.000453	0.00228	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Chlorambucil—hematologic cancer	0.000449	0.00226	CcSEcCtD
Methotrimeprazine—Photosensitivity—Methotrexate—hematologic cancer	0.000442	0.00222	CcSEcCtD
Methotrimeprazine—Constipation—Lenalidomide—hematologic cancer	0.000442	0.00222	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Nilotinib—hematologic cancer	0.00044	0.00221	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Imatinib—hematologic cancer	0.000437	0.0022	CcSEcCtD
Methotrimeprazine—CYP1A2—hematopoietic system—hematologic cancer	0.000436	0.0345	CbGeAlD
Methotrimeprazine—Constipation—Hydroxyurea—hematologic cancer	0.000436	0.00219	CcSEcCtD
Methotrimeprazine—Tachycardia—Thiotepa—hematologic cancer	0.000433	0.00218	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Cladribine—hematologic cancer	0.000429	0.00216	CcSEcCtD
Methotrimeprazine—Weight increased—Betamethasone—hematologic cancer	0.00042	0.00211	CcSEcCtD
Methotrimeprazine—Weight increased—Dexamethasone—hematologic cancer	0.00042	0.00211	CcSEcCtD
Methotrimeprazine—Tachycardia—Thalidomide—hematologic cancer	0.000419	0.0021	CcSEcCtD
Methotrimeprazine—Photosensitivity—Epirubicin—hematologic cancer	0.000414	0.00208	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Vinblastine—hematologic cancer	0.000412	0.00207	CcSEcCtD
Methotrimeprazine—HRH1—hematopoietic system—hematologic cancer	0.000408	0.0323	CbGeAlD
Methotrimeprazine—Constipation—Bortezomib—hematologic cancer	0.000407	0.00204	CcSEcCtD
Methotrimeprazine—Tachycardia—Carmustine—hematologic cancer	0.000402	0.00202	CcSEcCtD
Methotrimeprazine—ADRA2A—hematopoietic system—hematologic cancer	0.000401	0.0317	CbGeAlD
Methotrimeprazine—Tachycardia—Alitretinoin—hematologic cancer	0.000399	0.002	CcSEcCtD
Methotrimeprazine—Constipation—Vinorelbine—hematologic cancer	0.000397	0.002	CcSEcCtD
Methotrimeprazine—Somnolence—Thiotepa—hematologic cancer	0.000394	0.00198	CcSEcCtD
Methotrimeprazine—CYP2E1—hematopoietic system—hematologic cancer	0.000392	0.031	CbGeAlD
Methotrimeprazine—Hypersensitivity—Melphalan—hematologic cancer	0.000392	0.00197	CcSEcCtD
Methotrimeprazine—Photosensitivity—Doxorubicin—hematologic cancer	0.000383	0.00192	CcSEcCtD
Methotrimeprazine—Somnolence—Thalidomide—hematologic cancer	0.000382	0.00192	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Lenalidomide—hematologic cancer	0.000381	0.00191	CcSEcCtD
Methotrimeprazine—Constipation—Thiotepa—hematologic cancer	0.000379	0.00191	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Hydroxyurea—hematologic cancer	0.000376	0.00189	CcSEcCtD
Methotrimeprazine—Tachycardia—Mitoxantrone—hematologic cancer	0.000374	0.00188	CcSEcCtD
Methotrimeprazine—CHRM1—lung—hematologic cancer	0.000373	0.0295	CbGeAlD
Methotrimeprazine—Constipation—Thalidomide—hematologic cancer	0.000367	0.00184	CcSEcCtD
Methotrimeprazine—Somnolence—Carmustine—hematologic cancer	0.000366	0.00184	CcSEcCtD
Methotrimeprazine—Weight increased—Prednisone—hematologic cancer	0.000366	0.00184	CcSEcCtD
Methotrimeprazine—Somnolence—Alitretinoin—hematologic cancer	0.000363	0.00182	CcSEcCtD
Methotrimeprazine—Somnolence—Ifosfamide—hematologic cancer	0.000359	0.0018	CcSEcCtD
Methotrimeprazine—Acepromazine—SLC22A1—hematologic cancer	0.000355	0.12	CrCbGaD
Methotrimeprazine—Constipation—Carmustine—hematologic cancer	0.000352	0.00177	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Bortezomib—hematologic cancer	0.000351	0.00176	CcSEcCtD
Methotrimeprazine—ADRA1A—blood—hematologic cancer	0.000349	0.0276	CbGeAlD
Methotrimeprazine—Constipation—Alitretinoin—hematologic cancer	0.000349	0.00175	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Bleomycin—hematologic cancer	0.000348	0.00175	CcSEcCtD
Methotrimeprazine—Thioproperazine—SLC22A1—hematologic cancer	0.000347	0.117	CrCbGaD
Methotrimeprazine—Constipation—Ifosfamide—hematologic cancer	0.000345	0.00173	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Vinorelbine—hematologic cancer	0.000342	0.00172	CcSEcCtD
Methotrimeprazine—HTR2A—hematopoietic system—hematologic cancer	0.000341	0.0269	CbGeAlD
Methotrimeprazine—Pipotiazine—SLC22A1—hematologic cancer	0.000341	0.115	CrCbGaD
Methotrimeprazine—Somnolence—Mitoxantrone—hematologic cancer	0.000341	0.00171	CcSEcCtD
Methotrimeprazine—Somnolence—Irinotecan—hematologic cancer	0.000341	0.00171	CcSEcCtD
Methotrimeprazine—Tachycardia—Cisplatin—hematologic cancer	0.00034	0.00171	CcSEcCtD
Methotrimeprazine—Constipation—Vincristine—hematologic cancer	0.000336	0.00169	CcSEcCtD
Methotrimeprazine—ADRA2C—blood—hematologic cancer	0.000333	0.0263	CbGeAlD
Methotrimeprazine—Orthostatic hypotension—Epirubicin—hematologic cancer	0.000332	0.00167	CcSEcCtD
Methotrimeprazine—Somnolence—Gemcitabine—hematologic cancer	0.000332	0.00167	CcSEcCtD
Methotrimeprazine—Constipation—Mitoxantrone—hematologic cancer	0.000328	0.00165	CcSEcCtD
Methotrimeprazine—Constipation—Irinotecan—hematologic cancer	0.000328	0.00165	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Thiotepa—hematologic cancer	0.000327	0.00164	CcSEcCtD
Methotrimeprazine—Constipation—Gemcitabine—hematologic cancer	0.000319	0.0016	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Thalidomide—hematologic cancer	0.000316	0.00159	CcSEcCtD
Methotrimeprazine—CHRM3—testis—hematologic cancer	0.000315	0.0249	CbGeAlD
Methotrimeprazine—Tachycardia—Etoposide—hematologic cancer	0.000311	0.00156	CcSEcCtD
Methotrimeprazine—CYP2D6—hematopoietic system—hematologic cancer	0.000311	0.0245	CbGeAlD
Methotrimeprazine—Orthostatic hypotension—Doxorubicin—hematologic cancer	0.000307	0.00154	CcSEcCtD
Methotrimeprazine—Tachycardia—Prednisolone—hematologic cancer	0.000307	0.00154	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Methotrexate—hematologic cancer	0.000306	0.00154	CcSEcCtD
Methotrimeprazine—ADRA2A—gonad—hematologic cancer	0.000305	0.0241	CbGeAlD
Methotrimeprazine—Hypersensitivity—Carmustine—hematologic cancer	0.000304	0.00153	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Alitretinoin—hematologic cancer	0.000301	0.00151	CcSEcCtD
Methotrimeprazine—DRD2—lung—hematologic cancer	0.0003	0.0237	CbGeAlD
Methotrimeprazine—Drowsiness—Methotrexate—hematologic cancer	0.000299	0.0015	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Ifosfamide—hematologic cancer	0.000297	0.00149	CcSEcCtD
Methotrimeprazine—ADRA2C—lung—hematologic cancer	0.000292	0.0231	CbGeAlD
Methotrimeprazine—Clomipramine—GSTP1—hematologic cancer	0.000291	0.0987	CrCbGaD
Methotrimeprazine—Hypersensitivity—Vincristine—hematologic cancer	0.00029	0.00146	CcSEcCtD
Methotrimeprazine—CYP1A2—blood—hematologic cancer	0.000289	0.0228	CbGeAlD
Methotrimeprazine—Photosensitivity reaction—Epirubicin—hematologic cancer	0.000287	0.00144	CcSEcCtD
Methotrimeprazine—Weight increased—Epirubicin—hematologic cancer	0.000286	0.00144	CcSEcCtD
Methotrimeprazine—Somnolence—Etoposide—hematologic cancer	0.000283	0.00142	CcSEcCtD
Methotrimeprazine—DRD2—testis—hematologic cancer	0.000283	0.0224	CbGeAlD
Methotrimeprazine—Hypersensitivity—Mitoxantrone—hematologic cancer	0.000282	0.00142	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Irinotecan—hematologic cancer	0.000282	0.00142	CcSEcCtD
Methotrimeprazine—Tachycardia—Triamcinolone—hematologic cancer	0.000282	0.00142	CcSEcCtD
Methotrimeprazine—Drowsiness—Epirubicin—hematologic cancer	0.00028	0.00141	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Methotrexate—hematologic cancer	0.000279	0.0014	CcSEcCtD
Methotrimeprazine—ADRA2C—testis—hematologic cancer	0.000275	0.0218	CbGeAlD
Methotrimeprazine—Jaundice—Epirubicin—hematologic cancer	0.000273	0.00137	CcSEcCtD
Methotrimeprazine—Constipation—Etoposide—hematologic cancer	0.000273	0.00137	CcSEcCtD
Methotrimeprazine—ADRA2A—blood—hematologic cancer	0.000266	0.021	CbGeAlD
Methotrimeprazine—Photosensitivity reaction—Doxorubicin—hematologic cancer	0.000265	0.00133	CcSEcCtD
Methotrimeprazine—Weight increased—Doxorubicin—hematologic cancer	0.000265	0.00133	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Epirubicin—hematologic cancer	0.000261	0.00131	CcSEcCtD
Methotrimeprazine—CYP2E1—blood—hematologic cancer	0.00026	0.0205	CbGeAlD
Methotrimeprazine—HTR2A—gonad—hematologic cancer	0.000259	0.0205	CbGeAlD
Methotrimeprazine—Drowsiness—Doxorubicin—hematologic cancer	0.000259	0.0013	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Cisplatin—hematologic cancer	0.000256	0.00129	CcSEcCtD
Methotrimeprazine—Tachycardia—Betamethasone—hematologic cancer	0.000256	0.00129	CcSEcCtD
Methotrimeprazine—Tachycardia—Dexamethasone—hematologic cancer	0.000256	0.00129	CcSEcCtD
Methotrimeprazine—CYP1A2—lung—hematologic cancer	0.000253	0.02	CbGeAlD
Methotrimeprazine—Jaundice—Doxorubicin—hematologic cancer	0.000253	0.00127	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Doxorubicin—hematologic cancer	0.000242	0.00122	CcSEcCtD
Methotrimeprazine—HRH1—lung—hematologic cancer	0.000237	0.0187	CbGeAlD
Methotrimeprazine—Hypersensitivity—Etoposide—hematologic cancer	0.000235	0.00118	CcSEcCtD
Methotrimeprazine—ADRA2A—lung—hematologic cancer	0.000233	0.0184	CbGeAlD
Methotrimeprazine—Hypersensitivity—Prednisolone—hematologic cancer	0.000232	0.00116	CcSEcCtD
Methotrimeprazine—CYP2E1—lung—hematologic cancer	0.000228	0.018	CbGeAlD
Methotrimeprazine—HTR2A—blood—hematologic cancer	0.000226	0.0179	CbGeAlD
Methotrimeprazine—HRH1—testis—hematologic cancer	0.000224	0.0177	CbGeAlD
Methotrimeprazine—Tachycardia—Prednisone—hematologic cancer	0.000223	0.00112	CcSEcCtD
Methotrimeprazine—ADRA2A—testis—hematologic cancer	0.00022	0.0174	CbGeAlD
Methotrimeprazine—CYP2E1—testis—hematologic cancer	0.000215	0.017	CbGeAlD
Methotrimeprazine—Hypersensitivity—Triamcinolone—hematologic cancer	0.000213	0.00107	CcSEcCtD
Methotrimeprazine—CYP2D6—blood—hematologic cancer	0.000206	0.0163	CbGeAlD
Methotrimeprazine—ADRA2C—lymph node—hematologic cancer	0.0002	0.0158	CbGeAlD
Methotrimeprazine—HTR2A—lung—hematologic cancer	0.000198	0.0156	CbGeAlD
Methotrimeprazine—Constipation—Prednisone—hematologic cancer	0.000195	0.000981	CcSEcCtD
Methotrimeprazine—HTR2A—testis—hematologic cancer	0.000187	0.0148	CbGeAlD
Methotrimeprazine—Chlorpromazine—SLC22A1—hematologic cancer	0.000185	0.0626	CrCbGaD
Methotrimeprazine—Imipramine—SLC22A1—hematologic cancer	0.000184	0.0623	CrCbGaD
Methotrimeprazine—Tachycardia—Epirubicin—hematologic cancer	0.000174	0.000876	CcSEcCtD
Methotrimeprazine—CYP2D6—testis—hematologic cancer	0.00017	0.0135	CbGeAlD
Methotrimeprazine—Somnolence—Methotrexate—hematologic cancer	0.00017	0.000853	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Prednisone—hematologic cancer	0.000168	0.000845	CcSEcCtD
Methotrimeprazine—HRH1—lymph node—hematologic cancer	0.000162	0.0128	CbGeAlD
Methotrimeprazine—Tachycardia—Doxorubicin—hematologic cancer	0.000161	0.00081	CcSEcCtD
Methotrimeprazine—ADRA2A—lymph node—hematologic cancer	0.000159	0.0126	CbGeAlD
Methotrimeprazine—Somnolence—Epirubicin—hematologic cancer	0.000159	0.000798	CcSEcCtD
Methotrimeprazine—Constipation—Epirubicin—hematologic cancer	0.000153	0.000767	CcSEcCtD
Methotrimeprazine—Somnolence—Doxorubicin—hematologic cancer	0.000147	0.000738	CcSEcCtD
Methotrimeprazine—Constipation—Doxorubicin—hematologic cancer	0.000141	0.00071	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Methotrexate—hematologic cancer	0.000141	0.000707	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Epirubicin—hematologic cancer	0.000132	0.000661	CcSEcCtD
Methotrimeprazine—Diltiazem—ABCB1—hematologic cancer	0.000125	0.0423	CrCbGaD
Methotrimeprazine—Hypersensitivity—Doxorubicin—hematologic cancer	0.000122	0.000612	CcSEcCtD
Methotrimeprazine—Triflupromazine—ABCB1—hematologic cancer	0.000111	0.0377	CrCbGaD
Methotrimeprazine—Acepromazine—ALB—hematologic cancer	0.000108	0.0366	CrCbGaD
Methotrimeprazine—Thioproperazine—ALB—hematologic cancer	0.000106	0.0357	CrCbGaD
Methotrimeprazine—Pipotiazine—ALB—hematologic cancer	0.000104	0.0352	CrCbGaD
Methotrimeprazine—Fluphenazine—ABCB1—hematologic cancer	8.57e-05	0.029	CrCbGaD
Methotrimeprazine—Clomipramine—ALB—hematologic cancer	8.21e-05	0.0278	CrCbGaD
Methotrimeprazine—Clomipramine—ABCB1—hematologic cancer	7.84e-05	0.0265	CrCbGaD
Methotrimeprazine—Chlorprothixene—ABCB1—hematologic cancer	7.8e-05	0.0264	CrCbGaD
Methotrimeprazine—Trimipramine—ABCB1—hematologic cancer	7.21e-05	0.0244	CrCbGaD
Methotrimeprazine—Promethazine—ABCB1—hematologic cancer	6.94e-05	0.0235	CrCbGaD
Methotrimeprazine—Trifluoperazine—ABCB1—hematologic cancer	6.85e-05	0.0232	CrCbGaD
Methotrimeprazine—Chlorpromazine—ALB—hematologic cancer	5.63e-05	0.0191	CrCbGaD
Methotrimeprazine—Chlorpromazine—ABCB1—hematologic cancer	5.37e-05	0.0182	CrCbGaD
Methotrimeprazine—Imipramine—ABCB1—hematologic cancer	5.35e-05	0.0181	CrCbGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—CCND1—hematologic cancer	3.22e-06	1.58e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—JUN—hematologic cancer	3.22e-06	1.58e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—VEGFA—hematologic cancer	3.21e-06	1.58e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—TP53—hematologic cancer	3.2e-06	1.57e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	3.19e-06	1.57e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—CDKN1A—hematologic cancer	3.18e-06	1.56e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—STAT3—hematologic cancer	3.18e-06	1.56e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—CDKN1A—hematologic cancer	3.18e-06	1.56e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—PTEN—hematologic cancer	3.18e-06	1.56e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—NRAS—hematologic cancer	3.17e-06	1.56e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—PTEN—hematologic cancer	3.17e-06	1.56e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—PTEN—hematologic cancer	3.17e-06	1.55e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—CDKN1A—hematologic cancer	3.17e-06	1.55e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—PIK3CA—hematologic cancer	3.17e-06	1.55e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—MYC—hematologic cancer	3.17e-06	1.55e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—VEGFA—hematologic cancer	3.16e-06	1.55e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—PTEN—hematologic cancer	3.16e-06	1.55e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—MAPK8—hematologic cancer	3.16e-06	1.55e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—TGFB1—hematologic cancer	3.16e-06	1.55e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—CDKN1A—hematologic cancer	3.16e-06	1.55e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—CREBBP—hematologic cancer	3.15e-06	1.55e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling by GPCR—AKT1—hematologic cancer	3.15e-06	1.54e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—PTEN—hematologic cancer	3.15e-06	1.54e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	3.14e-06	1.54e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—STAT3—hematologic cancer	3.13e-06	1.54e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—CDKN1A—hematologic cancer	3.13e-06	1.53e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—MAPK3—hematologic cancer	3.13e-06	1.53e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—NRAS—hematologic cancer	3.12e-06	1.53e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—PTEN—hematologic cancer	3.12e-06	1.53e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—CDKN1A—hematologic cancer	3.12e-06	1.53e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—PTEN—hematologic cancer	3.11e-06	1.53e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—MAPK8—hematologic cancer	3.11e-06	1.52e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	3.11e-06	1.52e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—MAPK8—hematologic cancer	3.1e-06	1.52e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—HRAS—hematologic cancer	3.1e-06	1.52e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling by GPCR—AKT1—hematologic cancer	3.1e-06	1.52e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—AKT1—hematologic cancer	3.09e-06	1.52e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—MAPK8—hematologic cancer	3.09e-06	1.52e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—AKT1—hematologic cancer	3.08e-06	1.51e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—MAPK8—hematologic cancer	3.08e-06	1.51e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—EP300—hematologic cancer	3.08e-06	1.51e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	3.08e-06	1.51e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—AKT1—hematologic cancer	3.07e-06	1.51e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—IL2—hematologic cancer	3.07e-06	1.51e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—TP53—hematologic cancer	3.06e-06	1.5e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—HRAS—hematologic cancer	3.06e-06	1.5e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	3.06e-06	1.5e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—MAPK8—hematologic cancer	3.05e-06	1.5e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—AKT1—hematologic cancer	3.04e-06	1.49e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	3.04e-06	1.49e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—MAPK3—hematologic cancer	3.04e-06	1.49e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—MYC—hematologic cancer	3.04e-06	1.49e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	3.03e-06	1.49e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—TGFB1—hematologic cancer	3.03e-06	1.49e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—EP300—hematologic cancer	3.03e-06	1.49e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—EP300—hematologic cancer	3.03e-06	1.48e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—EP300—hematologic cancer	3.02e-06	1.48e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.02e-06	1.48e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—PIK3CA—hematologic cancer	3.02e-06	1.48e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—EP300—hematologic cancer	3.01e-06	1.48e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—EP300—hematologic cancer	3e-06	1.47e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—PIK3CA—hematologic cancer	3e-06	1.47e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	2.99e-06	1.47e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—SRC—hematologic cancer	2.99e-06	1.47e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—MAPK3—hematologic cancer	2.99e-06	1.47e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PIK3CD—hematologic cancer	2.99e-06	1.47e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—JUN—hematologic cancer	2.99e-06	1.46e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—PIK3CA—hematologic cancer	2.98e-06	1.46e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—PIK3CA—hematologic cancer	2.98e-06	1.46e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—EP300—hematologic cancer	2.97e-06	1.46e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—IL6—hematologic cancer	2.97e-06	1.45e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—EP300—hematologic cancer	2.97e-06	1.45e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—MYC—hematologic cancer	2.96e-06	1.45e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—ALB—hematologic cancer	2.95e-06	1.45e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—TGFB1—hematologic cancer	2.95e-06	1.45e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—SRC—hematologic cancer	2.95e-06	1.44e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—SRC—hematologic cancer	2.94e-06	1.44e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—SRC—hematologic cancer	2.93e-06	1.44e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—HRAS—hematologic cancer	2.93e-06	1.44e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—IL6—hematologic cancer	2.93e-06	1.44e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—KRAS—hematologic cancer	2.93e-06	1.43e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—SRC—hematologic cancer	2.92e-06	1.43e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—TP53—hematologic cancer	2.92e-06	1.43e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—VEGFA—hematologic cancer	2.92e-06	1.43e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—MYC—hematologic cancer	2.91e-06	1.43e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—TGFB1—hematologic cancer	2.9e-06	1.42e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	2.9e-06	1.42e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—SRC—hematologic cancer	2.89e-06	1.42e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	2.89e-06	1.42e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—STAT3—hematologic cancer	2.89e-06	1.42e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—SRC—hematologic cancer	2.88e-06	1.41e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PIK3CG—hematologic cancer	2.88e-06	1.41e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—NRAS—hematologic cancer	2.88e-06	1.41e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—TP53—hematologic cancer	2.88e-06	1.41e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—TP53—hematologic cancer	2.88e-06	1.41e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—VEGFA—hematologic cancer	2.87e-06	1.41e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—VEGFA—hematologic cancer	2.86e-06	1.4e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—VEGFA—hematologic cancer	2.85e-06	1.4e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—VEGFA—hematologic cancer	2.85e-06	1.39e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—STAT3—hematologic cancer	2.84e-06	1.39e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—STAT3—hematologic cancer	2.84e-06	1.39e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—NRAS—hematologic cancer	2.83e-06	1.39e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—NRAS—hematologic cancer	2.83e-06	1.39e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	2.83e-06	1.39e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—STAT3—hematologic cancer	2.83e-06	1.39e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PIK3R1—hematologic cancer	2.82e-06	1.38e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	2.82e-06	1.38e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—NRAS—hematologic cancer	2.82e-06	1.38e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—VEGFA—hematologic cancer	2.82e-06	1.38e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—STAT3—hematologic cancer	2.82e-06	1.38e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—NRAS—hematologic cancer	2.81e-06	1.38e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	2.81e-06	1.38e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—KRAS—hematologic cancer	2.81e-06	1.38e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—IL6—hematologic cancer	2.8e-06	1.37e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—HRAS—hematologic cancer	2.79e-06	1.37e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—STAT3—hematologic cancer	2.79e-06	1.37e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—NRAS—hematologic cancer	2.78e-06	1.36e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	2.78e-06	1.36e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	2.78e-06	1.36e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—MAPK3—hematologic cancer	2.76e-06	1.35e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—EP300—hematologic cancer	2.76e-06	1.35e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—HRAS—hematologic cancer	2.75e-06	1.35e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—HRAS—hematologic cancer	2.75e-06	1.35e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—AKT1—hematologic cancer	2.74e-06	1.34e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—KRAS—hematologic cancer	2.73e-06	1.34e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—MAPK3—hematologic cancer	2.71e-06	1.33e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—MAPK3—hematologic cancer	2.71e-06	1.33e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—AKT1—hematologic cancer	2.7e-06	1.32e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—MAPK3—hematologic cancer	2.7e-06	1.32e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—MAPK3—hematologic cancer	2.69e-06	1.32e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—KRAS—hematologic cancer	2.69e-06	1.32e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—PIK3CA—hematologic cancer	2.69e-06	1.32e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—MYC—hematologic cancer	2.68e-06	1.32e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—SRC—hematologic cancer	2.68e-06	1.31e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—TGFB1—hematologic cancer	2.68e-06	1.31e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—CREBBP—hematologic cancer	2.67e-06	1.31e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—IL6—hematologic cancer	2.67e-06	1.31e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—MAPK3—hematologic cancer	2.67e-06	1.31e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	2.66e-06	1.3e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—PIK3CA—hematologic cancer	2.66e-06	1.3e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—MYC—hematologic cancer	2.64e-06	1.29e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—IL6—hematologic cancer	2.64e-06	1.29e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—IL6—hematologic cancer	2.64e-06	1.29e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—MYC—hematologic cancer	2.63e-06	1.29e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—TGFB1—hematologic cancer	2.63e-06	1.29e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—TGFB1—hematologic cancer	2.63e-06	1.29e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—MYC—hematologic cancer	2.63e-06	1.29e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—TGFB1—hematologic cancer	2.62e-06	1.28e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—MYC—hematologic cancer	2.62e-06	1.28e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—TGFB1—hematologic cancer	2.61e-06	1.28e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	2.61e-06	1.28e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PIK3CB—hematologic cancer	2.61e-06	1.28e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—TP53—hematologic cancer	2.6e-06	1.27e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—MYC—hematologic cancer	2.59e-06	1.27e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—AKT1—hematologic cancer	2.59e-06	1.27e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—TGFB1—hematologic cancer	2.59e-06	1.27e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—MYC—hematologic cancer	2.59e-06	1.27e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	2.59e-06	1.27e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—PIK3CA—hematologic cancer	2.58e-06	1.27e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	2.58e-06	1.26e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	2.58e-06	1.26e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PIK3CD—hematologic cancer	2.53e-06	1.24e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—PIK3CA—hematologic cancer	2.51e-06	1.23e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—ALB—hematologic cancer	2.5e-06	1.23e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—TP53—hematologic cancer	2.5e-06	1.22e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—HRAS—hematologic cancer	2.49e-06	1.22e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—KRAS—hematologic cancer	2.48e-06	1.22e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—PIK3CA—hematologic cancer	2.47e-06	1.21e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	2.47e-06	1.21e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—AKT1—hematologic cancer	2.46e-06	1.21e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—AKT1—hematologic cancer	2.45e-06	1.2e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—KRAS—hematologic cancer	2.44e-06	1.2e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—PIK3CA—hematologic cancer	2.44e-06	1.2e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—KRAS—hematologic cancer	2.43e-06	1.19e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—AKT1—hematologic cancer	2.43e-06	1.19e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—AKT1—hematologic cancer	2.43e-06	1.19e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—TP53—hematologic cancer	2.43e-06	1.19e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—KRAS—hematologic cancer	2.43e-06	1.19e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—KRAS—hematologic cancer	2.42e-06	1.19e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—MYC—hematologic cancer	2.4e-06	1.18e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	2.4e-06	1.17e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—KRAS—hematologic cancer	2.4e-06	1.17e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PIK3R1—hematologic cancer	2.39e-06	1.17e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—TP53—hematologic cancer	2.39e-06	1.17e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	2.39e-06	1.17e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—HRAS—hematologic cancer	2.39e-06	1.17e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—IL6—hematologic cancer	2.38e-06	1.17e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—HRAS—hematologic cancer	2.32e-06	1.14e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—HRAS—hematologic cancer	2.29e-06	1.12e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—IL6—hematologic cancer	2.29e-06	1.12e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—PIK3CA—hematologic cancer	2.28e-06	1.12e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PTEN—hematologic cancer	2.25e-06	1.1e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—PIK3CA—hematologic cancer	2.24e-06	1.1e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—PIK3CA—hematologic cancer	2.24e-06	1.1e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—PIK3CA—hematologic cancer	2.24e-06	1.1e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—PIK3CA—hematologic cancer	2.23e-06	1.09e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—IL6—hematologic cancer	2.22e-06	1.09e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—PIK3CA—hematologic cancer	2.22e-06	1.09e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	2.22e-06	1.09e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PIK3CB—hematologic cancer	2.21e-06	1.08e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—TP53—hematologic cancer	2.2e-06	1.08e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—PIK3CA—hematologic cancer	2.2e-06	1.08e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—AKT1—hematologic cancer	2.2e-06	1.08e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	2.19e-06	1.08e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—IL6—hematologic cancer	2.19e-06	1.07e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—AKT1—hematologic cancer	2.17e-06	1.06e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—TP53—hematologic cancer	2.17e-06	1.06e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—TP53—hematologic cancer	2.16e-06	1.06e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—TP53—hematologic cancer	2.16e-06	1.06e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—TP53—hematologic cancer	2.15e-06	1.05e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—EP300—hematologic cancer	2.15e-06	1.05e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—TP53—hematologic cancer	2.13e-06	1.04e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—TP53—hematologic cancer	2.12e-06	1.04e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—AKT1—hematologic cancer	2.11e-06	1.03e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—HRAS—hematologic cancer	2.11e-06	1.03e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—HRAS—hematologic cancer	2.07e-06	1.02e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—HRAS—hematologic cancer	2.07e-06	1.01e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—HRAS—hematologic cancer	2.06e-06	1.01e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—HRAS—hematologic cancer	2.06e-06	1.01e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—AKT1—hematologic cancer	2.05e-06	1.01e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	2.04e-06	1e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—HRAS—hematologic cancer	2.04e-06	9.98e-06	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	2.03e-06	9.95e-06	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—AKT1—hematologic cancer	2.02e-06	9.89e-06	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—IL6—hematologic cancer	2.02e-06	9.89e-06	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—AKT1—hematologic cancer	1.99e-06	9.77e-06	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—IL6—hematologic cancer	1.98e-06	9.73e-06	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—IL6—hematologic cancer	1.98e-06	9.71e-06	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—IL6—hematologic cancer	1.97e-06	9.68e-06	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—TP53—hematologic cancer	1.97e-06	9.67e-06	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—IL6—hematologic cancer	1.97e-06	9.65e-06	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—IL6—hematologic cancer	1.95e-06	9.55e-06	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—IL6—hematologic cancer	1.94e-06	9.53e-06	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PTEN—hematologic cancer	1.91e-06	9.35e-06	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	1.89e-06	9.25e-06	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—AKT1—hematologic cancer	1.86e-06	9.12e-06	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—AKT1—hematologic cancer	1.83e-06	8.98e-06	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—AKT1—hematologic cancer	1.83e-06	8.97e-06	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—AKT1—hematologic cancer	1.83e-06	8.96e-06	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—AKT1—hematologic cancer	1.82e-06	8.93e-06	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—EP300—hematologic cancer	1.82e-06	8.92e-06	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—AKT1—hematologic cancer	1.82e-06	8.9e-06	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—IL6—hematologic cancer	1.81e-06	8.85e-06	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—AKT1—hematologic cancer	1.8e-06	8.81e-06	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	1.79e-06	8.79e-06	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	1.67e-06	8.17e-06	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.59e-06	7.79e-06	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PIK3CA—hematologic cancer	1.35e-06	6.6e-06	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—AKT1—hematologic cancer	1.3e-06	6.36e-06	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—AKT1—hematologic cancer	1.1e-06	5.39e-06	CbGpPWpGaD
